The efficacy of immunotherapy in superficial bladder tumors was first established in 1976 with BCG (Morales, Eidinger & Bruce, 1976), but no immunotherapy had been approved for the treatment of advanced disease, until anti-PD-1/PD-L1 monoclonal antibody were approved for the treatment of bladder cancer patients (Powles et al., 2017). Here, CD274 is linked to urinary bladder carcinoma.